Brief: Everest Medicines Announces New Drug Application Acceptance By Singapore HSA For Nefecon For The Treatment Of Primary IgA Nephropathy
06/04/2023 24:31
April 5 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES ANNOUNCES NEW DRUG APPLICATION
ACCEPTANCE BY
SINGAPORE HSA FOR NEFECON FOR THE TREATMENT OF PRIMARY IGA
NEPHROPATHY
Source text for Eikon: ID:nPn26lM67a
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region